Tapentadol is partially metabolized via the hepatic enzymes CYP2C9, CYP2C19, and CYP2D6 so it innately has interactions with medication that enrich or repress the activity/expression of a number of of those enzymes, along with with substrates of such enzymes (as a result of Competitors with the enzyme); some enzyme mediators/substrates https://helenn097wza8.yourkwikimage.com/user